{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:47:26Z","timestamp":1789015646488,"version":"build-2803163510"},"reference-count":26,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The optimal first-line treatment for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) diagnosed in early stages is largely undefined. We, therefore, analyzed 100 NLPHL patients treated in the randomized HD16 (early-stage favorable; n = 85) and HD17 (early-stage unfavorable; n = 15) studies. These studies investigated the omission of consolidation radiotherapy (RT) in patients with a negative interim positron emission tomography (iPET) (ie, Deauville score &amp;lt;3) after chemotherapy (HD16: 2\u00d7 doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD]; HD17: 2\u00d7 escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPP] plus 2\u00d7 ABVD). Patients with NLPHL treated in the HD16 and HD17 studies had 5-year progression-free survival (PFS) rates of 90.3% and 92.9%, respectively. Thus, the 5-year PFS did not differ significantly from that of patients with classical Hodgkin lymphoma treated within the same studies (HD16:\u00a0P\u00a0= .88; HD17:\u00a0P\u00a0= .50). Patients with early-stage favorable NLPHL who had a negative iPET after 2\u00d7 ABVD and did not undergo consolidation RT tended to have a worse 5-year PFS than patients with a negative iPET who received consolidation RT (83% vs 100%;\u00a0P\u00a0= .05). There were 10 cases of NLPHL recurrence. However, no NLPHL patient died during follow-up. Hence, the 5-year overall survival rate was 100%. Taken together, contemporary Hodgkin lymphoma-directed treatment approaches result in excellent outcomes for patients with newly diagnosed early-stage NLPHL and, thus, represent valid treatment options. In early-stage favorable NLPHL, consolidation RT appears necessary after 2\u00d7 ABVD to achieve the optimal disease control irrespective of the iPET result.<\/jats:p>","DOI":"10.1182\/blood.2023019939","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T21:03:56Z","timestamp":1685567036000},"page":"553-560","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-3514","authenticated-orcid":false,"given":"Dennis A.","family":"Eichenauer","sequence":"first","affiliation":[{"name":"1First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany"},{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"B\u00fchnen","sequence":"additional","affiliation":[{"name":"1First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany"},{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-6064","authenticated-orcid":false,"given":"Christian","family":"Baues","sequence":"additional","affiliation":[{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"},{"name":"3Department of Radiation Oncology, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"},{"name":"4Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kaul","sequence":"additional","affiliation":[{"name":"1First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany"},{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[{"name":"5Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Austrian Group for Medical Tumor Therapy, Paracelsus Medical University, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alden","family":"Moccia","sequence":"additional","affiliation":[{"name":"6Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"},{"name":"7Swiss Group for Clinical Cancer Research, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1074-5922","authenticated-orcid":false,"given":"Jose\u00e9 M.","family":"Zijlstra","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Amsterdam UMC, Vrije universiteit, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hertenstein","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine I, Klinikum Bremen-Mitte, Bremen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[{"name":"10Second Department of Internal Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Just","sequence":"additional","affiliation":[{"name":"11Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"},{"name":"12Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, German Cancer Consortium (DKTK partner site Essen), Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Theodor","family":"Eich","sequence":"additional","affiliation":[{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"},{"name":"13Department of Radiotherapy, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[{"name":"1First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany"},{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dietlein","sequence":"additional","affiliation":[{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"},{"name":"4Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Hartmann","sequence":"additional","affiliation":[{"name":"14Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"1First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany"},{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"1First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany"},{"name":"2German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2023081015251890600_bib1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/asheducation-2017.1.324","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management","volume":"2017","author":"Eichenauer","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2023081015251890600_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.16290","article-title":"Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016","volume":"189","author":"Posthuma","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"2023081015251890600_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"2023081015251890600_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to\u00a0aggressive lymphoma in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023081015251890600_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2023081015251890600_bib6","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023081015251890600_bib7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin\u2019s lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2023081015251890600_bib8","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.2019004044","article-title":"How I treat nodular lymphocyte-predominant Hodgkin lymphoma","volume":"136","author":"Eichenauer","year":"2020","journal-title":"Blood"},{"key":"2023081015251890600_bib9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.19.00986","article-title":"Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group","volume":"38","author":"Eichenauer","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023081015251890600_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte\u2013predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2023081015251890600_bib11","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood.2019003877","article-title":"Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG","volume":"135","author":"Binkley","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2023081015251890600_bib12","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1080\/10428194.2022.2053533","article-title":"Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW)","volume":"63","author":"Lo","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023081015251890600_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.18169","article-title":"Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma \u2014 All StAGEs: a consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute","volume":"197","author":"Shankar","year":"2022","journal-title":"Br J Haematol"},{"issue":"18","key":"2023081015251890600_bib14","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/bloodadvances.2021004375","article-title":"Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach","volume":"5","author":"Cheng","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2023081015251890600_bib15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"31","key":"2023081015251890600_bib16","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography\u2013guided treatment in early-stage favorable Hodgkin lymphoma: final results of the nternational, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023081015251890600_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17","key":"2023081015251890600_bib18","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2023081015251890600_bib19","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2023081015251890600_bib20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023081015251890600_bib21","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers13081760","article-title":"Rituximab-containing risk-adapted treatment strategy in nodular lymphocyte predominant Hodgkin lymphoma: 7-years follow-up","volume":"13","author":"Pugliese","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2023081015251890600_bib22","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.2015.133025","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study","volume":"100","author":"Lazarovici","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"2023081015251890600_bib23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hon.2986","article-title":"Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"40","author":"Eichenauer","year":"2022","journal-title":"Hematol Oncol"},{"issue":"14","key":"2023081015251890600_bib24","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2018-02-836437","article-title":"Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","volume":"132","author":"Eichenauer","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2023081015251890600_bib25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/bjh.17281","article-title":"Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis","volume":"192","author":"Strati","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"2023081015251890600_bib26","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/ajh.25607","article-title":"The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma","volume":"94","author":"Hartmann","year":"2019","journal-title":"Am J Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/6\/553\/2070100\/blood_bld-2023-019939-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/6\/553\/2070100\/blood_bld-2023-019939-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T15:27:24Z","timestamp":1691681244000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/6\/553\/496128\/Interim-PET-guided-treatment-for-early-stage-NLPHL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023019939","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}